Last reviewed · How we verify
Placebo matching mepolizumab
Mepolizumab is an IL-5 inhibitor, which works by binding to the IL-5 protein and preventing it from interacting with its receptor on the surface of eosinophils, thereby reducing eosinophilic inflammation.
Mepolizumab is an IL-5 inhibitor, which works by binding to the IL-5 protein and preventing it from interacting with its receptor on the surface of eosinophils, thereby reducing eosinophilic inflammation. Used for Severe asthma with an eosinophilic phenotype, Chronic rhinosinusitis with nasal polyposis.
At a glance
| Generic name | Placebo matching mepolizumab |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | IL-5 inhibitor |
| Target | IL-5 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-5 is a cytokine that plays a key role in the production and survival of eosinophils, a type of white blood cell involved in allergic reactions and asthma. By inhibiting IL-5, mepolizumab reduces the number of eosinophils in the body, which can help alleviate symptoms of asthma and other eosinophilic disorders.
Approved indications
- Severe asthma with an eosinophilic phenotype
- Chronic rhinosinusitis with nasal polyposis
Common side effects
- Injection site reaction
- Headache
- Nausea
- Fatigue
Key clinical trials
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA） (PHASE2, PHASE3)
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (PHASE3)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (PHASE3)
- A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma (PHASE3)
- Effect of Mepolizumab in Severe Bilateral Nasal Polyps (PHASE3)
- Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching mepolizumab CI brief — competitive landscape report
- Placebo matching mepolizumab updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI